Saccone G, Mastantuoni E, Ferrara C, Sglavo G, Zizolfi B, De Angelis M C, Di Spiezio Sardo A
Facts Views Vis Obgyn. 2022 Mar;14(1):83-86. doi: 10.52054/FVVO.14.1.008.
Caesarean scar pregnancy (CSP) is a type of ectopic pregnancy where the fertilised egg is implanted in the muscle or fibrous tissue of the scar after a previous caesarean section. Management options for women who opted for termination of CSP include sharp curettage, dilation and evacuation (D&E), excision of trophoblastic tissues, local or systemic administration of methotrexate, bilateral hypogastric artery ligation, and selective uterine artery embolisation with curettage and/or methotrexate administration. Recently hysteroscopic resection has also been proposed as an alternative option.
To compare the surgical outcome of hysteroscopic resection with dilation and evacuation (D&E) for the treatment of caesarean scar pregnancy (CSP).
Parallel-group, non-blinded, randomised clinical trial conducted at a single centre in Italy. Eligible women are those with singleton gestations at less than 9 weeks of gestation, and with thickness of myometrial layer ≥1 mm at the level of the ectopic. Inclusion criteria are women with CSP with positive embryonic/fetal heart activity who opted for termination of pregnancy. Patients will be randomised 1:1 to receive either hysteroscopic resection (i.e. intervention group) or D&E (i.e. control group). In both groups, 50 mg/m2 (based on DuBois formula for body surface area) of methotrexate (MTX) will be injected intramuscularly at the time of randomisation (day 1) and another dose at day 3. A third dose of MTX is planned in case of persistence of fetal heart activity on day 5. Participants will receive either D&E or hysteroscopic resection from 3 to 7 days after the last dose of MTX. A sample size of 54 women is planned.
The primary outcome is the success rate of the treatment protocol, defined as no requirement for further treatment until complete resolution of the CSP as demonstrated by negative beta hCG levels and absence of residual gestational material on ultrasound examination..
Hysteroscopic surgery is superior to D&E for the treatment of CSP.
WHAT IS NEW?: The results of the trial will provide information on the best treatment for CSP.
剖宫产瘢痕妊娠(CSP)是一种异位妊娠,即受精卵在前次剖宫产术后植入瘢痕的肌肉或纤维组织中。对于选择终止CSP妊娠的女性,治疗方案包括刮宫术、扩张刮宫术(D&E)、滋养层组织切除术、甲氨蝶呤局部或全身给药、双侧髂内动脉结扎以及选择性子宫动脉栓塞术并结合刮宫术和/或甲氨蝶呤给药。最近,宫腔镜切除术也被提议作为一种替代方案。
比较宫腔镜切除术与扩张刮宫术(D&E)治疗剖宫产瘢痕妊娠(CSP)的手术效果。
在意大利的一个中心进行平行组、非盲法、随机临床试验。符合条件的女性为单胎妊娠且妊娠小于9周,异位妊娠部位的肌层厚度≥1mm。纳入标准为CSP且胚胎/胎儿心跳活动阳性并选择终止妊娠的女性。患者将按1:1随机分组,分别接受宫腔镜切除术(即干预组)或D&E(即对照组)。两组在随机分组时(第1天)均肌内注射50mg/m²(基于杜波依斯体表面积公式)甲氨蝶呤(MTX),并在第3天注射另一剂。若第5天仍有胎儿心跳活动,则计划注射第三剂MTX。参与者将在最后一剂MTX后的3至7天接受D&E或宫腔镜切除术。计划样本量为54名女性。
主要结局是治疗方案的成功率,定义为直至CSP完全消退无需进一步治疗,即β-hCG水平呈阴性且超声检查无残留妊娠物。
宫腔镜手术治疗CSP优于D&E。
该试验结果将为CSP的最佳治疗提供信息。